Ms Miller is concerned that the proliferation of AI on both sides of the recruitment process is causing "a race to the bottom".
A combination of two therapies, azacitidine and venetoclax, or aza-ven, outperformed intensive chemotherapy for acute myeloid leukemia in patients healthy enough to receive aggressive treatment, ...